• METTL17 Modulates Ferroptosis via Mitochondrial Translation

  2026-08-05

  This study identifies METTL17 as a pivotal regulator of ferroptosis resistance and tumorigenesis in colorectal cancer (CRC) by modulating mitochondrial RNA methylation and translation. The findings provide new mechanistic insight into mitochondrial-mediated cell death and highlight METTL17 as a potential therapeutic target to sensitize CRC cells to ferroptosis-based interventions.

• SCUBE3 Antibody Targeting Suppresses Tumor Growth and Immune

  2026-08-05

  This study establishes secretory SCUBE3 as a critical driver of oncogenic signaling and tumor immune suppression. Antibody-mediated targeting of SCUBE3 disrupts key interactions with EGFR and other receptors, impeding cancer proliferation and therapy resistance, and restoring antitumor immunity. The findings highlight SCUBE3 as a promising pan-cancer therapeutic target and provide mechanistic insights into overcoming resistance in aggressive malignancies.

• Mild ER Stress Activation Boosts Cadmium Resistance in C. el

  2026-08-04

  This study reveals that moderate induction of the endoplasmic reticulum unfolded protein response (UPRER) significantly enhances cadmium resistance in Caenorhabditis elegans. The findings clarify the mechanistic role of the IRE-1/XBP-1 signaling axis in detoxification and protein homeostasis, providing a foundation for future research on environmental toxicant resistance.

• Coumestrol Induces Ferroptosis in RA-FLS via PMAIP1 Stabiliz

  2026-08-04

  This study demonstrates that Coumestrol, a phytoestrogen estrogen receptor antagonist, selectively induces ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) by stabilizing mitochondrial PMAIP1. The findings highlight a novel mechanism for suppressing synovial proliferation and inflammation, providing a foundation for new therapeutic strategies in rheumatoid arthritis.

• Dacomitinib (PF-00299804): Pan-HER Inhibition in Cancer Mode

  2026-08-03

  Dacomitinib (PF-00299804) is a potent, irreversible pan-HER inhibitor that targets EGFR, HER2, and HER4, demonstrating nanomolar activity and robust induction of cell cycle arrest and apoptosis in resistant cancer cell lines. This article details its mechanism, experimental benchmarks, and current limits, providing a structured foundation for oncology and mitochondrial research.

• Trelagliptin Succinate Improves Insulin Sensitivity via PI-3

  2026-08-03

  A recent study elucidates how trelagliptin succinate, a DPP-4 inhibitor, improves insulin resistance in adipocytes by modulating the PI-3K/AKT/GLUT4 axis. These mechanistic insights provide a foundation for further research into targeted interventions for metabolic disorders and highlight key methodological considerations for phosphorylation state analysis.

• AZD2461: Novel PARP Inhibitor for Advanced Breast Cancer Res

  2026-08-02

  AZD2461 sets a new benchmark as a novel PARP inhibitor, enabling researchers to dissect DNA repair pathways and overcome Pgp-mediated resistance in breast cancer models. Its unique pharmacology and robust in vitro performance expand opportunities for both mechanistic studies and translational oncology applications.

• Paroxetine Mesylate: Multi-Target Mechanisms and Translation

  2026-08-01

  Explore how Paroxetine Mesylate, a selective serotonin reuptake inhibitor, uniquely integrates SSRI activity with multi-kinase and P450 inhibition to drive both neuropsychiatric and oncology research. This article delivers advanced mechanistic insights and protocol guidance distinct from prior literature.

• 17-AAG (Tanespimycin): Applied HSP90 Inhibition in Cancer Wo

  2026-07-31

  17-AAG (Tanespimycin) empowers cancer researchers with potent, selective HSP90 chaperone inhibition, enabling robust client protein degradation and apoptosis across diverse models. This guide delivers actionable workflow enhancements, troubleshooting insights, and protocol parameters to maximize reproducibility and translational impact.

• AG-490 (Tyrphostin B42): Unlocking JAK2/STAT6 Research in HC

  2026-07-31

  AG-490 (Tyrphostin B42) empowers researchers to dissect JAK2/STAT6-driven macrophage polarization in hepatocellular carcinoma. This guide decodes protocol optimization, troubleshooting, and advanced use-cases, leveraging both recent mechanistic breakthroughs and APExBIO’s trusted formulation.

• (Z)-4-Hydroxytamoxifen: Precision Control of ER Signaling in

  2026-07-30

  (Z)-4-Hydroxytamoxifen is a potent estrogen receptor modulator enabling unparalleled precision in modeling estrogen-dependent breast cancer. This article uniquely explores its mechanistic advantages and critical role in designing next-generation preclinical assays, offering insights beyond conventional protocols.

• Bifendate (DDB): Multiomics Insights for Precision Hepatopro

  2026-07-30

  Explore how Bifendate (DDB) leverages multiomics analysis to redefine the landscape of hepatoprotection. This article provides an in-depth, evidence-driven look at its mechanisms, unique regulatory targets, and implications for liver research.

• TSPAN18 Stabilizes STIM1 to Drive Bone Metastasis in Prostat

  2026-07-29

  Zhou et al. identified TSPAN18 as a critical regulator of STIM1 stability, protecting it from TRIM32-mediated ubiquitination and promoting calcium entry in prostate cancer cells. This mechanism drives bone metastasis, offering new insight into metastatic progression and highlighting TSPAN18 as a promising therapeutic target.

• Machine Learning Accelerates Senolytic Discovery in Oncology

  2026-07-29

  The referenced study demonstrates the power of machine learning to identify novel senolytic compounds, significantly reducing the cost and time of drug discovery. By validating senolytic activity in human cell lines, the work offers new directions for research on targeted elimination of senescent cells in cancer and age-related diseases.

• N1-Methyl-Pseudouridine-5'-Triphosphate in Localized mRNA Ca

  2026-07-28

  Explore how N1-Methyl-Pseudouridine-5'-Triphosphate (N1-Methylpseudo-UTP) enables next-generation mRNA therapeutics through enhanced RNA stability and precision delivery. This article uniquely focuses on localized tumor suppressor mRNA therapy, drawing practical insights from recent breakthroughs.

16074 records 1/1072 page Next 12345 下5页 Last page